Is mirtazapine appropriate for treating insomnia?

Mirtazapine for Sleep: Not Recommended as First-Line

Mirtazapine is not recommended as a first-line treatment for chronic insomnia disorder in adults. Major clinical practice guidelines from the American Academy of Sleep Medicine (AASM) and American College of Physicians do not include mirtazapine among recommended pharmacologic treatments for insomnia 1, 2.

Guideline-Based Recommendations

The 2017 AASM clinical practice guideline explicitly evaluated multiple pharmacologic agents for chronic insomnia but did not include mirtazapine in their recommendations 2. Instead, they provide WEAK recommendations for:

• Sleep onset and maintenance: eszopiclone, zolpidem, temazepam
• Sleep maintenance only: suvorexant, doxepin
• Sleep onset only: zaleplon, triazolam, ramelteon

The 2016 American College of Physicians evidence report similarly found insufficient evidence for antidepressants (including mirtazapine) in treating insomnia disorder, with only eszopiclone, zolpidem, and suvorexant showing low-to-moderate strength evidence for efficacy 1.

FDA Labeling and Off-Label Use

Mirtazapine is FDA-approved only for major depressive disorder, not insomnia 3. The FDA label explicitly states to "take mirtazapine tablets 1 time each day, preferably in the evening at bedtime" for depression treatment, acknowledging its sedating properties 3. However, this timing recommendation relates to managing side effects in depression treatment, not treating primary insomnia.

Key Safety Concerns from FDA Labeling:

• Prominent somnolence (54% vs 18% placebo), leading to 10.4% discontinuation 3
• Significant weight gain (7.5% gained ≥7% body weight vs 0% placebo) and increased appetite (17% vs 2%) 3
• QTc prolongation with potential for cardiac arrhythmias, particularly at higher doses or with other risk factors 3
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), which can be fatal 3
• Hyponatremia, especially in elderly patients 3
• Activation of mania/hypomania in bipolar disorder 3

Recent Research Evidence: Mixed Results

While recent studies show some efficacy, they reveal important limitations:

The 2025 MIRAGE trial (the highest quality recent evidence) demonstrated mirtazapine 7.5 mg was superior to placebo in older adults with chronic insomnia, reducing ISI scores by -6.5 points vs -2.9 for placebo at 28 days 4. However, 6 participants discontinued due to adverse events in the mirtazapine group vs only 1 in placebo, limiting clinical utility 4.

The 2025 DREAMING trial found mirtazapine 7.5-15 mg showed statistically significant improvement at 6 weeks (ISI reduction -6.0 points vs placebo), but this benefit disappeared by 12 weeks and beyond 5. This suggests tolerance development and questions long-term efficacy.

Clinical Algorithm for Decision-Making

If considering mirtazapine for insomnia, use this approach:

1. First, ensure guideline-recommended treatments have been tried or contraindicated: eszopiclone, zolpidem, suvorexant, or doxepin 2

2. Consider mirtazapine only if:

   • Comorbid major depression exists (its approved indication) 6
   • Patient is underweight or has poor appetite (weight gain becomes therapeutic)
   • Guideline-recommended agents failed or are contraindicated
   • Patient is NOT elderly with fall risk (somnolence + orthostatic hypotension) 3

3. Screen for contraindications:

   • Bipolar disorder history (risk of mania activation) 3
   • Cardiac disease or QT prolongation risk 3
   • Concurrent QTc-prolonging medications 3
   • Concerns about weight gain 3

4. If prescribing:

   • Start with 7.5 mg at bedtime (ultra-low dosing shows efficacy) 7, 4
   • Reassess at 6 weeks; if no benefit, discontinue (tolerance likely develops) 5
   • Monitor for weight gain, next-day sedation, and mood changes
   • Taper gradually if discontinuing (avoid withdrawal syndrome) 3

Critical Pitfalls to Avoid

• Do not use mirtazapine as first-line for primary insomnia when guideline-recommended agents are available and appropriate
• Do not assume sedation equals therapeutic benefit for insomnia—the mechanism differs from approved hypnotics
• Do not continue indefinitely—evidence suggests efficacy may wane after 6-12 weeks 5
• Do not overlook weight gain and metabolic effects, particularly problematic in patients with obesity or metabolic syndrome
• Do not use in elderly patients without careful fall risk assessment—combination of somnolence, orthostatic hypotension, and hyponatremia risk is substantial 3, 4

Bottom Line

Mirtazapine remains an off-label option for insomnia without guideline support. Its use should be reserved for specific clinical scenarios—primarily when comorbid depression exists or when guideline-recommended treatments have failed. The recent high-quality evidence shows short-term efficacy but significant adverse events and questionable durability of benefit 4, 5. The risk-benefit ratio favors guideline-recommended agents for primary insomnia treatment 1, 2.